Compare GROW & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | NEPH |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 31.0M |
| IPO Year | 1995 | 2004 |
| Metric | GROW | NEPH |
|---|---|---|
| Price | $3.19 | $3.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.3K | ★ 53.0K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ 106.67 |
| EPS | 0.05 | ★ 0.10 |
| Revenue | ★ $23,850,609.00 | $14,162,000.00 |
| Revenue This Year | N/A | $12.82 |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | $63.80 | ★ $30.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.05 | $1.49 |
| 52 Week High | $3.65 | $6.42 |
| Indicator | GROW | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 31.46 |
| Support Level | $3.10 | $2.89 |
| Resistance Level | $3.43 | $4.93 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 34.46 | 13.98 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.